



13, quai Godefroid Kurth  
4020 LIEGE  
BELGIUM

email: [esceoasbl@skynet.be](mailto:esceoasbl@skynet.be)  
Tel: +32 4 344 37 69  
Fax: +32 4 341 23 14  
TVA: BE0877 737 261

Chief Executive Officer  
Olivier BRUYERE

President  
Jean-Yves REGINSTER

Vice President  
Cyrus COOPER

Honorary President  
John A. KANIS

General Secretary  
Maria Luisa BRANDI

Treasurer  
Jean-Marc KAUFMAN

Board Member  
Etienne CAVALIER

Chairman of the Scientific  
Advisory Board  
René RIZZOLI

Members of the Scientific

Advisor Board  
Donato AGNUSDEI  
Kristina AKESSON  
Nigel ARDEN  
Jürgen BAUER  
Ivan BAUTMANS  
Charlotte BEAUDART  
Emmanuel BIVER  
Jean-Jacques BODY  
Andrew BORG  
Mary BOUXSEIN  
Maria-Luisa BRANDI  
Olivier BRUYERE  
Fanny BUCKINX  
Nansa BURLET  
Etienne CAVALIER  
Matteo CESARI  
Roland CHAPURLAT  
Antonio CHERUBINI  
Thierry CHEVALLEY  
Juliet COMPTON  
Cyrus COOPER  
Bernard CORDET  
Alfonso CRUZ-JENTOFT  
Edward CZERWINSKI  
Bess DAWSON-HUGHES  
Elaine DENNISON  
Jean-Pierre DEVOGELAER  
Hans Peter DIMAI  
Roger FIELDING  
Serge FERRARI  
Andrea GASPARIK  
Nicholas HARVEY  
Mickaël HILIGSMANN  
Helena JOHANSSON  
John A. KANIS  
Jean-Marc KAUFMAN  
Francesco LANDI  
Paul LIPS  
Roman LORENC  
George LYRITIS  
Stefania MAGGI  
Johanne MARTEL-PELLETIER  
Eugene McCLOSKEY  
Xavier NOGUES  
Julien PACCOU  
Socrates PAPAPOULOS  
Karel PAVELKA  
Jean-Pierre PELLETIER  
Daniel PINTO  
Daniel PRIETO-ALHAMBRA  
Jean-Yves REGINSTER  
Johann RINGE  
René RIZZOLI  
Yves ROLLAND  
Christian ROUX  
Cornel SIEBER  
Pavel SZULC  
Thierry THOMAS  
Bruno VELLAS

To Whom it may concern

## Process of inclusion of R.E.M.S. technology into clinical practice guidelines for the diagnostic and treatment of osteoporosis.

The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) is a not-for-profit organization, dedicated to a close interaction between clinical scientists dealing with bone, joint and muscle disorders, industry developing new compounds in this field, regulators responsible for the registration of such drugs and health policy makers, to integrate the management of Osteoporosis and Osteoarthritis within the comprehensive perspective of health resources utilization.

Evidence-based clinical practice guidelines (CPGs), serve as a framework for clinical decisions and supporting best practices including recommendations intended to optimize patient care. They are developed by a systematic review of evidence, and an assessment of the benefits and harms of alternative care options. CPGs follow a sound, transparent methodology to translate best evidence into clinical practice for improved patient outcomes.

ESCEO follows a well-defined periodic process in the adoption of CPGs. In the process of definition of the Guideline for the diagnostic and treatment of Osteoporosis are involved several medical specialties such as Endocrinology, Gynecology, Rheumatology, Geriatrics, Orthopedics and others. We apply rigorous evidence-based methodology and at the same time drive the adoption of innovations into clinical practice.

Lately, several clinical studies on R.E.M.S. (Radiofrequency Echographic Multi Spectrometry), an innovative technique for early osteoporosis diagnosis and treatment monitoring, have been published in specialized journals (R.E.M.S. compared with dual X-ray absorptiometry for osteoporosis diagnosis on lumbar spine and femoral neck, *Osteoporos Int* 2018; An advanced quantitative echosound methodology for femoral neck densitometry, *Ultrasound Med Biol* 2016; A novel ultrasound methodology for estimating spine mineral density, *Ultrasound Med Biol* 2015; and others) motivating the inclusion of this new technology as a topic for the dedicated 2018/2019 ESCEO Working Group: *"Radiofrequency Echographic Multi Spectrometry for the Assessment of in Vivo Bone Strength: State of the Art"*.

ESCEO is considering to write a position paper discussing the potentialities of R.E.M.S. technology in the perspective of the early diagnosis of osteoporosis and of the monitoring of treatments and this new method will certainly be considered at the next revision of the ESCEO CPGs.

The objective of ESCEO is to provide practitioners with the latest clinical and economic information, allowing them to organize their daily practice, in an evidence-based medicine perspective, with a cost-conscious perception.

Liege, 21 September 2018  
Prof Dr. Jean- Yves Reginster  
PRESIDENT ESCEO